Treatment of Bronchial Asthma with Unani medicine Habb-e-Hindi Zeeqi

Phase 2

Not yet recruiting

• Conditions: Chronic lower respiratory diseases, (2) ICD-10 Condition: J459||Other and unspecified asthma, (3) ICD-10 Condition: J459||Other and unspecified asthma,

• Registration Number: CTRI/2018/10/015906
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM

Brief Summary

This study is designed as a multicentric open trial in patients with **Zeequn Nafas(Bronchial Asthma)** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically at every week.  This includes subjective assessment of general well being and physical examination . The total duration of treatment will be Four weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy. 

**Composition of Habb-e-Hindi Zeeqi**

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical / Chemical Name**

**Quantity**

|1.

Beesh Mudbbar

*Aconitum ferox* Wall. Ex. Ser.

15gm

|2.

Post-e-Bekh-e-Madar

*Calotropis procera* (Ait) R. Br.

30gm

|3.

Aab-e-Adrak

*Zingiber officinale* Rosc

30 gm

Detailed Description

Not available

Study Timeline

• Study Start: 2018-08-10
• Last Update Posted: 2019-02-18

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• Males and females of 18-65 years 2.
• Objective evidence for reversible airway obstruction (≥12% and ≥200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment 3.
• Asthma for at least 6 months before enrollment.

Exclusion Criteria

• The patients of Zeeq-un-Nafas (Bronchial Asthma) with following conditions will be excluded from the study: 1.
• FEV1/FVC ratio < 50% 2.
• Pregnant and lactating mother 3.
• Patient with other Respiratory Tract Infections, tuberculosis and malignancy.
• Patient with co-morbidities, Diabetes Mellitus, Hepatic and Renal Insufficiency.
• Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Zeequn Nafas(Bronchial Asthma)	Four weeks

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	At baseline and end of treatment

Trial Locations

Locations (1)

Regional Research Institute of Unani Medicine; 🇮🇳 Patna, BIHAR, India

Regional Research Institute of Unani Medicine

🇮🇳Patna, BIHAR, India

Dr Fakhre Alam

Principal investigator

9411653041

fakhrealamx7598@gmail.com

Dr Naquibul Islam

Principal investigator

9469154930

naquibislam@gmail.com

Dr Rajesh

Principal investigator

8544424962

drrajesh.baba@gmail.com